| Ytd | 66.29% | |
| 1y | -11.50% |
| Open | 13.61 | Prev Close | 13.49 | Low | 13.28 | High | 14.00 | Mkt Cap | 132.58M |
| Vol | 0.00 | Avg Vol | 195.89K | EPS | -10.00 | P/E | -1.33 | Forward P/E | -4.29 |
| Beta | 3.04 | Short Ratio | 2.64 | Inst. Own | 91.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 12.19 | 200-d Avg | 12.99 | 1yr Est | 137.76 |
KRRO News
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consen
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track
Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report)
CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biophar
Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The lates
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar
Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class trans
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopha
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have earned an average rating of "Moderat
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a bio
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients w
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have received an average rating of "Hold"
